Foundry Healthcare DelCOA Factor ETF
ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Hypothetical growth of $1 — long-short backtest
Gross of the placeholder expense ratio and trading costs · not investor results
Holdings
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1BMY | BRISTOL MYERS SQUIBB CO | Healthcare | $124.04B | 22.74% |
2CI | CIGNA GROUP | Healthcare | $74.45B | 13.65% |
3RVMD | REVOLUTION MEDICINES INC | Healthcare | $39.58B | 7.26% |
4CNC | CENTENE CORP | Healthcare | $32.81B | 6.01% |
5DXCM | DEXCOM INC | Healthcare | $29.58B | 5.42% |
6MRNA | MODERNA INC | Healthcare | $24.53B | 4.50% |
7UTHR | UNITED THERAPEUTICS CORP | Healthcare | $22.74B | 4.17% |
8BTSG | BRIGHTSPRING HEALTH SERVICES INC | Healthcare | $13.71B | 2.51% |
9MOH | MOLINA HEALTHCARE INC | Healthcare | $11.74B | 2.15% |
10BMRN | BIOMARIN PHARMACEUTICAL INC | Healthcare | $11.52B | 2.11% |
11CYTK | CYTOKINETICS INC | Healthcare | $9.98B | 1.83% |
12CORT | CORCEPT THERAPEUTICS INC | Healthcare | $9.72B | 1.78% |
13HALO | HALOZYME THERAPEUTICS INC | Healthcare | $9.23B | 1.69% |
14PTGX | PROTAGONIST THERAPEUTICS INC | Healthcare | $9.06B | 1.66% |
15ALKS | ALKERMES PLC | Healthcare | $8.79B | 1.61% |
16SRRK | SCHOLAR ROCK HOLDING CORP | Healthcare | $6.33B | 1.16% |
17ERAS | ERASCA INC | Healthcare | $5.96B | 1.09% |
18DFTX | DEFINIUM THERAPEUTICS INC | Healthcare | $4.83B | 0.89% |
19VKTX | VIKING THERAPEUTICS INC | Healthcare | $4.31B | 0.79% |
20ICUI | ICU MEDICAL INC | Healthcare | $3.94B | 0.72% |
21DOCS | DOXIMITY INC | Healthcare | $3.94B | 0.72% |
22RLAY | RELAY THERAPEUTICS INC | Healthcare | $3.81B | 0.70% |
23DNLI | DENALI THERAPEUTICS INC | Healthcare | $3.70B | 0.68% |
24RCUS | ARCUS BIOSCIENCES INC | Healthcare | $3.44B | 0.63% |
25IDYA | IDEAYA BIOSCIENCES INC | Healthcare | $3.16B | 0.58% |
26RARE | ULTRAGENYX PHARMACEUTICAL INC | Healthcare | $2.88B | 0.53% |
27CLDX | CELLDEX THERAPEUTICS INC | Healthcare | $2.77B | 0.51% |
28VERA | VERA THERAPEUTICS INC | Healthcare | $2.76B | 0.51% |
29IMNM | IMMUNOME INC | Healthcare | $2.53B | 0.46% |
30PGNY | PROGYNY INC | Healthcare | $2.50B | 0.46% |
31NRIX | NURIX THERAPEUTICS INC | Healthcare | $2.40B | 0.44% |
32BCRX | BIOCRYST PHARMACEUTICALS INC | Healthcare | $2.36B | 0.43% |
33AGIO | AGIOS PHARMACEUTICALS INC | Healthcare | $2.36B | 0.43% |
34BHVN | BIOHAVEN LTD | Healthcare | $2.32B | 0.43% |
35IOVA | IOVANCE BIOTHERAPEUTICS INC | Healthcare | $2.23B | 0.41% |
36SION | SIONNA THERAPEUTICS INC | Healthcare | $2.23B | 0.41% |
37AGL | AGILON HEALTH INC | Healthcare | $2.17B | 0.40% |
38CDNA | CAREDX INC | Healthcare | $2.05B | 0.38% |
39SNDX | SYNDAX PHARMACEUTICALS INC | Healthcare | $2.02B | 0.37% |
40AMLX | AMYLYX PHARMACEUTICALS INC | Healthcare | $1.97B | 0.36% |
41NVCR | NOVOCURE LTD | Healthcare | $1.84B | 0.34% |
42SRPT | SAREPTA THERAPEUTICS INC | Healthcare | $1.82B | 0.33% |
43ZYME | ZYMEWORKS INC | Healthcare | $1.77B | 0.32% |
44ANAB | ANAPTYSBIO INC | Healthcare | $1.69B | 0.31% |
45FTRE | FORTREA HOLDINGS INC | Healthcare | $1.68B | 0.31% |
46INVA | INNOVIVA INC | Healthcare | $1.60B | 0.29% |
47VIR | VIR BIOTECHNOLOGY INC | Healthcare | $1.59B | 0.29% |
48NTLA | INTELLIA THERAPEUTICS INC | Healthcare | $1.59B | 0.29% |
49INSP | INSPIRE MEDICAL SYSTEMS INC | Healthcare | $1.46B | 0.27% |
50MLTX | MOONLAKE IMMUNOTHERAPEUTICS | Healthcare | $1.45B | 0.27% |
51SDGR | SCHRODINGER INC | Healthcare | $1.14B | 0.21% |
52EYPT | EYEPOINT INC | Healthcare | $1.12B | 0.20% |
53PCRX | PACIRA BIOSCIENCES INC | Healthcare | $1.01B | 0.18% |
54KURA | KURA ONCOLOGY INC | Healthcare | $964M | 0.18% |
55ANNX | ANNEXON INC | Healthcare | $950M | 0.17% |
56REPL | REPLIMUNE GROUP INC | Healthcare | $859M | 0.16% |
57BBNX | BETA BIONICS INC | Healthcare | $771M | 0.14% |
58AURA | AURA BIOSCIENCES INC | Healthcare | $723M | 0.13% |
59SPRY | ARS PHARMACEUTICALS INC | Healthcare | $695M | 0.13% |
60EVH | EVOLENT HEALTH INC | Healthcare | $654M | 0.12% |
61ACHV | ACHIEVE LIFE SCIENCES INC | Healthcare | $644M | 0.12% |
62NGNE | NEUROGENE INC | Healthcare | $590M | 0.11% |
63WEAV | WEAVE COMMUNICATIONS INC | Healthcare | $575M | 0.11% |
64ARVN | ARVINAS INC | Healthcare | $517M | 0.09% |
65RGNX | REGENXBIO INC | Healthcare | $511M | 0.09% |
66SGMT | SAGIMET BIOSCIENCES INC | Healthcare | $479M | 0.09% |
67CCRN | CROSS COUNTRY HEALTHCARE INC | Healthcare | $428M | 0.08% |
68ENTA | ENANTA PHARMACEUTICALS INC | Healthcare | $400M | 0.07% |
69EBS | EMERGENT BIOSOLUTIONS INC | Healthcare | $394M | 0.07% |
70STRO | SUTRO BIOPHARMA INC | Healthcare | $391M | 0.07% |
71UPB | UPSTREAM BIO INC | Healthcare | $382M | 0.07% |
72ZNTL | ZENTALIS PHARMACEUTICALS INC | Healthcare | $364M | 0.07% |
73VNDA | VANDA PHARMACEUTICALS INC | Healthcare | $327M | 0.06% |
74LYEL | LYELL IMMUNOPHARMA INC | Healthcare | $311M | 0.06% |
75FHTX | FOGHORN THERAPEUTICS INC | Healthcare | $305M | 0.06% |
76TKNO | ALPHA TEKNOVA INC | Healthcare | $291M | 0.05% |
77TRDA | ENTRADA THERAPEUTICS INC | Healthcare | $268M | 0.05% |
78ARTV | ARTIVA BIOTHERAPEUTICS INC | Healthcare | $241M | 0.04% |
79SPOK | SPOK HOLDINGS INC | Healthcare | $222M | 0.04% |
80KPTI | KARYOPHARM THERAPEUTICS INC | Healthcare | $216M | 0.04% |
81KROS | KEROS THERAPEUTICS INC | Healthcare | $211M | 0.04% |
82AMWL | AMERICAN WELL CORP | Healthcare | $199M | 0.04% |
83PDEX | PRO DEX INC | Healthcare | $183M | 0.03% |
84ARCT | ARCTURUS THERAPEUTICS HOLDINGS INC | Healthcare | $172M | 0.03% |
85RCEL | AVITA MEDICAL INC | Healthcare | $157M | 0.03% |
86PMN | PROMIS NEUROSCIENCES INC | Healthcare | $136M | 0.02% |
87AARD | AARDVARK THERAPEUTICS INC | Healthcare | $128M | 0.02% |
88JYNT | JOINT CORP | Healthcare | $127M | 0.02% |
89SPRB | SPRUCE BIOSCIENCES INC | Healthcare | $120M | 0.02% |
90RLYB | RALLYBIO CORP | Healthcare | $87M | 0.02% |
91ACET | ADICET BIO INC | Healthcare | $76M | 0.01% |
92ATRA | ATARA BIOTHERAPEUTICS INC | Healthcare | $76M | 0.01% |
93MCRB | SERES THERAPEUTICS INC | Healthcare | $52M | 0.01% |
94EXOZ | EXOZYMES INC | Healthcare | $51M | 0.01% |
95TIL | INSTIL BIO INC | Healthcare | $50M | 0.01% |
Full long-leg book as of July 2026 · cap-weighted · total market cap $545.49B. Hypothetical model holdings — not a registered fund’s portfolio.
Sector Breakdown
Portfolio Style
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 92% toward Large, 38% toward Growth. +3% unclassified (10 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → July 2026; the right-hand end is the same value as the box’s dot. 95 names now. The faded start covers early months with a much thinner universe. Hypothetical holdings — descriptive, not P&L.
Constraint checks
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.
Required>= 75.0%Actual69.9%Margin-5.1%
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700
Measured on the 2026-07 formation date across 95 holdings (cap-weighted). A different formation date can produce different verdicts.
Derivatives risk (Rule 18f-4)
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months
The estimators agree, which is mild evidence the number isn’t an artefact of one method.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Since publication
Did the edge survive the paper coming out?
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Consistency across eras
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Returns
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 64.7% | -2.0% |
| 3 yearsp.a. | 10.4% | -13.4% |
| 5 yearsp.a. | 2.3% | -7.8% |
| 10 yearsp.a. | 6.1% | -6.2% |
| Since inceptionp.a. | 12.0% | 3.0% |
| Year | Long leg | Long-short |
|---|---|---|
| 20267 mo | 19.1% | 3.9% |
| 2025 | 23.5% | -8.1% |
| 2024 | -7.3% | -28.0% |
| 2023 | 4.7% | -9.1% |
| 2022 | -13.8% | 3.3% |
| 2021 | -6.1% | -17.3% |
| 2020 | 7.0% | -27.9% |
| 2019 | 19.9% | -0.9% |
| 2018 | -1.1% | 6.9% |
| 2017 | 32.7% | 22.5% |
| 2016 | -2.7% | 17.5% |
| 2015 | 10.5% | 5.8% |
| 2014 | 25.5% | -2.0% |
| 2013 | 43.2% | -1.6% |
| 2012 | 34.1% | 24.4% |
| 2011 | 13.1% | 10.0% |
| 2010 | 16.5% | 12.4% |
| 2009 | 11.1% | -10.9% |
| 2008 | -18.2% | 2.8% |
| 2007 | 1.3% | -21.4% |
| 2006 | 17.0% | 9.4% |
| 2005 | -3.0% | -11.1% |
| 2004 | -6.3% | -16.1% |
| 2003 | 80.3% | 57.0% |
| 2002 | -38.5% | -14.0% |
| 2001 | 19.7% | 57.1% |
| 2000 | 79.3% | 27.9% |
| 1999 | 46.5% | 54.7% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
Fund Facts
Methodology
The Foundry Healthcare DelCOA Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a DelCOA signal and holds the top quintile with the lowest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Documents (draft — hypothetical)
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.